92 related articles for article (PubMed ID: 11113685)
1. Epidemiological analysis of patients with Type 2 diabetes in France.
Grimaldi A; Grangé V; Allannic H; Passa P; Rodier M; Cornet P; Duprat I; Duc-Dodon P; Lemaire A; Liard F; Eschwège E
J Diabetes Complications; 2000; 14(5):242-9. PubMed ID: 11113685
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of acarbose efficacy and safety for treatment of diabetes mellitus. Testing of observations under general health care conditions].
Sieradzki J; Soszyński P
Przegl Lek; 1999; 56(5):335-41. PubMed ID: 10554569
[TBL] [Abstract][Full Text] [Related]
3. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
[TBL] [Abstract][Full Text] [Related]
4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
5. [Prevalence of diabetes, antidiabetic treatment and chronic diabetic complications reported by general practitioners].
Fabian W; Majkowska L; Stefański A; Moleda P
Przegl Lek; 2005; 62(4):201-5. PubMed ID: 16229234
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type II diabetes mellitus. A model of medicine-based evidence.
Scorpiglione N; Belfiglio M; Carinci F; Cavaliere D; De Curtis A; Franciosi M; Mari E; Sacco M; Tognoni G; Nicolucci A
Eur J Clin Pharmacol; 1999 Jun; 55(4):239-49. PubMed ID: 10424314
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of diabetes mellitus in Western pacific region: focus on Philippines.
Lantion-Ang LC
Diabetes Res Clin Pract; 2000 Oct; 50 Suppl 2():S29-34. PubMed ID: 11024581
[TBL] [Abstract][Full Text] [Related]
8. Management of French patients with type 2 diabetes mellitus in medical general practice: report of the Mediab observatory.
Monnier L; Grimaldi A; Charbonnel B; Iannascoli F; Lery T; Garofano A; Childs M;
Diabetes Metab; 2004 Feb; 30(1):35-42. PubMed ID: 15029096
[TBL] [Abstract][Full Text] [Related]
9. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
10. The prevalence of Type 2 diabetes and related complications in a nationally representative sample of adults aged 50 and over in the Republic of Ireland.
Tracey ML; McHugh SM; Buckley CM; Canavan RJ; Fitzgerald AP; Kearney PM
Diabet Med; 2016 Apr; 33(4):441-5. PubMed ID: 26112979
[TBL] [Abstract][Full Text] [Related]
11. Association of diabetic retinopathy, ischemic heart disease, and albuminuria with diabetic treatment in type 2 diabetic patients. A population-based study.
Weitzman S; Maislos M; Bodner-Fishman B; Rosen S
Acta Diabetol; 1997 Dec; 34(4):275-9. PubMed ID: 9451472
[TBL] [Abstract][Full Text] [Related]
12. [Type 2 diabetic patients in a population sample from Ribeirão Preto area (São Paulo)].
Foss MC; Paccola GM; de Souza NV; Iazigi N
AMB Rev Assoc Med Bras; 1989; 35(5):179-83. PubMed ID: 2486414
[TBL] [Abstract][Full Text] [Related]
13. Impact of late complications in type 2 diabetes in a Dutch population.
Verhoeven S; van Ballegooie E; Casparie AF
Diabet Med; 1991 Jun; 8(5):435-8. PubMed ID: 1830527
[TBL] [Abstract][Full Text] [Related]
14. Managing type 2 diabetes in France: the ECODIA survey.
Detournay B; Cros S; Charbonnel B; Grimaldi A; Liard F; Cogneau J; Fagnani F; Eschwège E
Diabetes Metab; 2000 Nov; 26(5):363-9. PubMed ID: 11119015
[TBL] [Abstract][Full Text] [Related]
15. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
Mosenzon O; Raz I; Scirica BM; Hirshberg B; Stahre CI; Steg PG; Davidson J; Ohman P; Price DL; Frederich B; Udell JA; Braunwald E; Bhatt DL
Diabetes Metab Res Rev; 2013 Jul; 29(5):417-26. PubMed ID: 23564755
[TBL] [Abstract][Full Text] [Related]
16. Is acarbose equivalent to tolbutamide as first treatment for newly diagnosed type 2 diabetes in general practice? A randomised controlled trial.
van de Laar FA; Lucassen PL; Kemp J; van de Lisdonk EH; van Weel C; Rutten GE
Diabetes Res Clin Pract; 2004 Jan; 63(1):57-65. PubMed ID: 14693413
[TBL] [Abstract][Full Text] [Related]
17. Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting: effects of 2 years of gliclazide treatment--the Diadem Study.
Cathelineau G; de Champvallins M; Bouallouche A; Lesobre B
Metabolism; 1997 Dec; 46(12 Suppl 1):31-4. PubMed ID: 9439556
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of diagnosed type 2 diabetes mellitus in the French general population: the INSTANT study.
Bringer J; Fontaine P; Detournay B; Nachit-Ouinekh F; Brami G; Eschwege E
Diabetes Metab; 2009 Feb; 35(1):25-31. PubMed ID: 19046913
[TBL] [Abstract][Full Text] [Related]
19. Rationale, study design and methodology of the LANDMARC trial: a 3-year, pan-India, prospective, longitudinal study to assess management and real-world outcomes of diabetes mellitus.
Das AK; Mithal A; Kumar KMP; Unnikrishnan AG; Kalra S; Thacker H; Sethi B; Ghosh R; Mathew A; Chodankar D; Mohanasundaram S; Menon SK; Trivedi C; Naqvi M; Kanade V; Salvi V; Chatterjee G; Rais N; Wangnoo SK; Chowdhury S; Zargar AH; Joshi S
Diabet Med; 2020 May; 37(5):885-892. PubMed ID: 31691356
[TBL] [Abstract][Full Text] [Related]
20. Comparison of risk factors of macrovascular complications. Peripheral vascular disease, cerebral vascular disease, and coronary heart disease in Japanese type 2 diabetes mellitus patients.
Asakawa H; Tokunaga K; Kawakami F
J Diabetes Complications; 2000; 14(6):307-13. PubMed ID: 11120454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
